BIOMARIN PHARMACEUTICAL INC Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of 3.40% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-02-26
- BIOMARIN PHARMACEUTICAL INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2025 was 3.40%.
- BIOMARIN PHARMACEUTICAL INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2017 was 19.10%, a 315.22% increase from fiscal 2016.
- BIOMARIN PHARMACEUTICAL INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2016 was 4.60%.
- BIOMARIN PHARMACEUTICAL INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2015 was -2.80%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | 3.40% 10-K · filed 2026-02-26 | |
| 2017-12-31 | 19.10% 10-K · filed 2018-02-26 | |
| 2016-12-31 | 4.60% 10-K · filed 2018-02-26 | |
| 2015-12-31 | -2.80% 10-K · filed 2018-02-26 | 2.80% 10-K · filed 2016-02-29 |
| 2014-12-31 | -2.40% 10-K · filed 2017-02-27 | |
| 2013-12-31 | 1.70% 10-K · filed 2016-02-29 | -1.70% 10-K · filed 2015-03-02 |
| 2012-12-31 | -1.60% 10-K · filed 2015-03-02 | |
| 2011-12-31 | -1.60% 10-K · filed 2014-02-26 | -8.20% 10-K · filed 2012-02-22 |
| 2010-12-31 | -8.20% 10-K · filed 2014-02-26 | -12.70% 10-K · filed 2012-02-22 |
| 2009-12-31 | 683.50% 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |